Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Operating expenses | ||||||||||
| General and administrative | $ 1,366,464 | $ 1,582,059 | $ 4,685,241 | $ 5,112,002 | $ 6,584,868 | $ 4,499,923 | ||||
| Research and development | 758,759 | 745,506 | 2,475,596 | 2,059,769 | 2,672,836 | 1,562,927 | ||||
| Total operating expenses | 2,125,223 | 2,327,565 | 7,160,837 | 7,171,771 | 9,257,704 | 6,062,850 | ||||
| Other (income) and expenses | ||||||||||
| Forgiveness of accounts payable | (416,000) | (416,000) | ||||||||
| Warrant liability (income) expense | (77,237) | (77,237) | 12,784,329 | |||||||
| Unrealized loss (gain) | (2,119) | 3,053 | 11,926 | 3,053 | (1,307) | |||||
| Interest income | (196,425) | (15,132) | (536,068) | (15,132) | (95,745) | |||||
| Interest and financing expense | 714,081 | 714,081 | 714,081 | 1,090,409 | ||||||
| Total other (income) expense | (198,544) | 702,002 | (524,142) | 208,765 | 123,792 | 15,399,738 | ||||
| Net loss | (1,926,679) | $ (2,106,947) | $ (2,603,069) | (3,029,567) | $ (2,668,167) | $ (1,682,802) | (6,636,695) | (7,380,536) | (9,381,496) | (21,462,588) |
| Deemed dividend on warrant modification | (65,266) | (65,266) | (65,266) | |||||||
| Net loss attributable to shareholders | $ (1,926,679) | $ (3,094,833) | $ (6,636,695) | $ (7,445,802) | $ (9,446,762) | $ (21,462,588) | ||||
| ADS | ||||||||||
| Loss per ADS | ||||||||||
| Basic | $ (1.95) | $ (11.28) | $ (7.61) | $ (55.79) | $ (46.80) | $ (815.54) | ||||
| Fully-diluted | $ (1.95) | $ (11.28) | $ (7.61) | $ (55.79) | $ (46.80) | $ (815.54) | ||||
| Weighted average number of ADS's outstanding | ||||||||||
| Basic | 987,220 | 274,317 | 871,835 | 133,450 | 201,826 | 26,317 | ||||
| Fully-diluted | 987,220 | 274,317 | 871,835 | 133,450 | 201,826 | 26,317 | ||||
| X | ||||||||||
- Definition Amount of deemed dividends on warrant modification. No definition available.
|
| X | ||||||||||
- Definition Amount of interest and financing expenses. No definition available.
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|